{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:23:17Z","timestamp":1789741397671,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006507","name":"FIOCRUZ","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006507","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.vaccine.2015.03.077","type":"journal-article","created":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T03:28:48Z","timestamp":1428636528000},"page":"4261-4268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures"],"prefix":"10.1016","volume":"33","author":[{"given":"Renata C.","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea N.M.R.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Cristina O.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon V.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia P.C.C.","family":"Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea A.M.V.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise D.C.S.","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.O.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.Y.","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos S.","family":"Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciane P.","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Caride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.03.077_bib0205","series-title":"Molecular biology of the flavivirus","first-page":"1","article-title":"The molecular biology of yellow fever virus","author":"Kummerer","year":"2006"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0210","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cll.2010.01.001","article-title":"Yellow fever: a reemerging threat","volume":"30","author":"Gardner","year":"2010","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1473-3099(01)00016-0","article-title":"Yellow fever: an update","volume":"1","author":"Monath","year":"2001","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2015.03.077_bib0220","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1590\/S0037-86822003000200012","article-title":"Febre amarela","volume":"36","author":"Vasconcelos","year":"2003","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0225","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/14760584.4.4.553","article-title":"Yellow fever vaccine","volume":"4","author":"Monath","year":"2005","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0230","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0020-7519(03)00063-8","article-title":"Traditional and novel approaches to flavivirus vaccines","volume":"33","author":"Pugachev","year":"2003","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0235","series-title":"Minist\u00e9rio da Sa\u00fade. Departamento Nacional de Endemias Rurais. Hist\u00f3ria da febre amarela no Brasil","author":"Franco","year":"1976"},{"issue":"28","key":"10.1016\/j.vaccine.2015.03.077_bib0240","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1016\/j.vaccine.2010.03.023","article-title":"Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity","volume":"14","author":"Monath","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0245","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coi.2009.05.018","article-title":"Yellow fever vaccine\u2014how does it work and why do rare cases of serious adverse events take place?","volume":"21","author":"Barrett","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0250","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(01)05326-0","article-title":"Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases","volume":"358","author":"Vasconcelos","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0255","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/erv.12.6","article-title":"Review of the risks and benefits of yellow fever vaccination including some new analyses","volume":"11","author":"Monath","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0260","first-page":"2798","article-title":"Development of a membrane adsorber based capture step for the purification of yellow fever virus","volume":"24","author":"Pato","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0265","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.biologicals.2012.09.005","article-title":"Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies","volume":"40","author":"Sim\u00f5es","year":"2012","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0270","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/10408360490497474","article-title":"Yellow fever: the recurring plague","volume":"41","author":"Tomori","year":"2004","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0275","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.qco.0000178823.28585.ad","article-title":"New developments in flavivirus vaccines with special attention to yellow fever","volume":"18","author":"Pugachev","year":"2005","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0280","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/bit.24493","article-title":"Vaccine process technology","volume":"109","author":"Josefsberg","year":"2012","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0285","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1586\/erv.12.38","article-title":"Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges","volume":"11","author":"Delrue","year":"2012","journal-title":"Expert Rev Vaccines"},{"issue":"3518","key":"10.1016\/j.vaccine.2015.03.077_bib0290","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/bmj.1.3518.976","article-title":"A yellow fever vaccine","volume":"1","author":"Hindle","year":"1928","journal-title":"Br Med J"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0295","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4049\/jimmunol.30.3.221","article-title":"A study of inactivated yellow fever virus as immunizing agent","volume":"30","author":"Gordon","year":"1936","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0300","first-page":"29","article-title":"The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to cutter vaccine","volume":"78","author":"Nathanson","year":"1963","journal-title":"Am J Hyg"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0305","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1752-8062.2010.00205.x","article-title":"Lessons from the Salk polio vaccine: methods for and risks of rapid translation","volume":"3","author":"Juskewitch","year":"2010","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0310","doi-asserted-by":"crossref","first-page":"36198","DOI":"10.1074\/jbc.M111.279232","article-title":"Reactions of \u03b2-propiolactone with nucleobase analogues, nucleosides, and peptides: implications for the inactivation of viruses","volume":"286","author":"Uittenbogaard","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0315","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/sj.jim.2900391","article-title":"Production methods for rabies vaccine","volume":"18","author":"Perez","year":"1997","journal-title":"J Ind Microbiol"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0320","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/157489106778777673","article-title":"Advances in the development of inactivated virus vaccines","volume":"1","author":"Stauffer","year":"2006","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0325","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jviromet.2008.03.002","article-title":"Pressure-inactivated yellow fever 17DD virus: implications for vaccine development","volume":"150","author":"Gaspar","year":"2008","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0330","doi-asserted-by":"crossref","first-page":"e81953","DOI":"10.1371\/journal.pone.0081953","article-title":"Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses","volume":"8","author":"Neves PC1","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0335","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.vaccine.2008.12.062","article-title":"Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study","volume":"27","author":"Schuller","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0340","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2310\/7060.2005.12205","article-title":"Protection against tick-borne encephalitis with a new vaccine formulation free of protein-derived stabilizers","volume":"12","author":"Zent","year":"2005","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0345","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1009303","article-title":"An inactivated cell-culture vaccine against yellow fever","volume":"364","author":"Monath","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0350","first-page":"129","article-title":"Dengue vaccine candidates in development","volume":"338","author":"Durbin","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0355","series-title":"Vaccines","first-page":"1095","article-title":"Yellow fever vaccine","author":"Monath","year":"2004"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0360","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0365","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2\u20133 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0370","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri2629","article-title":"Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology","volume":"9","author":"Pulendran","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0375","doi-asserted-by":"crossref","first-page":"8183","DOI":"10.1016\/j.vaccine.2010.09.090","article-title":"CD8+ gamma-delta TCR+ and CD4+ T cells produce IFN-gamma at 5\u20137 days after yellow fever vaccination in Indian rhesus macaques, before the induction of classical antigen-specific T cell responses","volume":"28","author":"Neves","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0380","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"Monath","year":"2015","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0385","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature06939","article-title":"Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants","volume":"453","author":"Eisenbarth","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0390","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1462-5822.2011.01609.x","article-title":"Optimizing vaccine development","volume":"13","author":"Hoft","year":"2011","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0395","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/eji.1830250329","article-title":"Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo","volume":"25","author":"Germann","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2015.03.077_bib0400","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.virol.2010.12.020","article-title":"Antibody-mediated neutralization of flaviviruses: a reductionist view","volume":"41","author":"Dowd","year":"2011","journal-title":"Virology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15003965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15003965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T09:56:42Z","timestamp":1691575002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15003965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":40,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0264410X15003965"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.077","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}